Effects of a diabetes drug on fat tissue in kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have chronic kidney disease (stages 1 through 4) and are not on dialysis.
- You have uncontrolled type 2 diabetes, heart disease, or obesity.
- You are willing to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
This study tests whether adding dulaglutide (a weekly injection) to two medications you may already be taking—an SGLT2 inhibitor and finerenone—helps protect your kidneys and controls blood sugar better in people with type 2 diabetes and chronic kidney disease.
This study tests whether SGLT2 inhibitors, a type of diabetes medication, can help reduce fat buildup in the liver (NAFLD) for people with type 2 diabetes who also have moderate kidney problems (stage 3 or 4 CKD). It may offer a new way to treat both conditions together.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This study tests whether a medication called an SGLT2 inhibitor (canagliflozin-like) can help slow kidney disease in people with type 1 diabetes. It may help protect your kidneys if you already have protein in your urine and reduced kidney function.
Hear when a new Chronic Kidney Disease stage3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.